[Recent progress in diagnosis of and therapy for patients with leukemia].
Ueda
Takanori
T
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage*; D016903:Drug Monitoring; D016044:Fusion Proteins, bcr-abl; D018390:Gene Targeting; D016162:Genes, Wilms Tumor; D015316:Genetic Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000628:therapy*; D009363:Neoplasm Proteins; D018365:Neoplasm, Residual / Q000235:genetics; D015514:Oncogene Proteins, Fusion; D010597:Pharmacogenetics; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins; D013810:Therapeutic Equivalency; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D003561:Cytarabine; D014212:Tretinoin; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl